To further determine whether the function of IGF2BP3 is dependent on p53, we used doxorubicin and etoposide, as DNA damage agents which can induce p53 activation [36, 37], to treat A549 (p53 positive) and H1299 (p53 negative) lung cancer cell lines in the presence of IGF2BP3 or not. Here, IGF2BP3 is linked to lung carcinoma.